These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35659371)

  • 1. Polymorphisms in common antihypertensive targets: Pharmacogenomic implications for the treatment of cardiovascular disease.
    Brown D; Alcala H; Oelschlaeger P; Andresen BT
    Adv Pharmacol; 2022; 94():141-182. PubMed ID: 35659371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenomic approaches to study the effects of antihypertensive drugs.
    Kamide K; Kawano Y; Rakugi H
    Hypertens Res; 2012 Aug; 35(8):796-9. PubMed ID: 22739423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational and Pharmacogenomic Insights on Hypertension Treatment: Rational Drug Design and Optimization Strategies.
    Loganathan L; Gopinath K; Sankaranarayanan VM; Kukreti R; Rajendran K; Lee JK; Muthusamy K
    Curr Drug Targets; 2020; 21(1):18-33. PubMed ID: 31393243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of antihypertensive treatment.
    Arnett DK; Claas SA; Glasser SP
    Vascul Pharmacol; 2006 Feb; 44(2):107-18. PubMed ID: 16356784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of antihypertensive drug responses.
    Schwartz GL; Turner ST
    Am J Pharmacogenomics; 2004; 4(3):151-60. PubMed ID: 15174896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the pharmacogenetics of treating hypertension.
    Fontana V; Luizon MR; Sandrim VC
    J Hum Hypertens; 2015 May; 29(5):283-91. PubMed ID: 25355012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
    Hiltunen TP; Donner KM; Sarin AP; Saarela J; Ripatti S; Chapman AB; Gums JG; Gong Y; Cooper-DeHoff RM; Frau F; Glorioso V; Zaninello R; Salvi E; Glorioso N; Boerwinkle E; Turner ST; Johnson JA; Kontula KK
    J Am Heart Assoc; 2015 Jan; 4(1):e001521. PubMed ID: 25622599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics of hypertension.
    Cadman PE; O'Connor DT
    Curr Opin Nephrol Hypertens; 2003 Jan; 12(1):61-70. PubMed ID: 12496668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of Hypertension Treatment.
    Rysz J; Franczyk B; Rysz-Górzyńska M; Gluba-Brzózka A
    Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32630286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics considerations in the control of hypertension.
    Lupoli S; Salvi E; Barcella M; Barlassina C
    Pharmacogenomics; 2015 Nov; 16(17):1951-64. PubMed ID: 26555875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
    McDonough CW; Gong Y; Padmanabhan S; Burkley B; Langaee TY; Melander O; Pepine CJ; Dominiczak AF; Cooper-Dehoff RM; Johnson JA
    Hypertension; 2013 Jul; 62(1):48-54. PubMed ID: 23690342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
    Vandell AG; Lobmeyer MT; Gawronski BE; Langaee TY; Gong Y; Gums JG; Beitelshees AL; Turner ST; Chapman AB; Cooper-DeHoff RM; Bailey KR; Boerwinkle E; Pepine CJ; Liggett SB; Johnson JA
    Hypertension; 2012 Oct; 60(4):957-64. PubMed ID: 22949529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of blood pressure response to antihypertensive treatment.
    Mellen PB; Herrington DM
    J Hypertens; 2005 Jul; 23(7):1311-25. PubMed ID: 15942450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations.
    Baudin B
    Pharmacogenomics; 2002 Jan; 3(1):65-73. PubMed ID: 11966404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
    Danilov SM; Tovsky SI; Schwartz DE; Dull RO
    J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):374-386. PubMed ID: 28587581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Physiologic Approach to the Pharmacogenomics of Hypertension.
    Eadon MT; Chapman AB
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):91-105. PubMed ID: 26979148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Individual sensitivity to antihypertensive drugs: genetic aspects].
    Minushkina LO; Zateĭshchikov DA; Sidorenko BA
    Kardiologiia; 2005; 45(7):58-65. PubMed ID: 16091664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene markers and antihypertensive therapy.
    Turner ST; Schwartz GL
    Curr Hypertens Rep; 2005 Feb; 7(1):21-30. PubMed ID: 15683583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.